In order to enable an iCal export link, your account needs to have an API key created. This key enables other applications to access data from within Indico even when you are neither using nor logged into the Indico system yourself with the link provided. Once created, you can manage your key at any time by going to 'My Profile' and looking under the tab entitled 'HTTP API'. Further information about HTTP API keys can be found in the Indico documentation.
Additionally to having an API key associated with your account, exporting private event information requires the usage of a persistent signature. This enables API URLs which do not expire after a few minutes so while the setting is active, anyone in possession of the link provided can access the information. Due to this, it is extremely important that you keep these links private and for your use only. If you think someone else may have acquired access to a link using this key in the future, you must immediately create a new key pair on the 'My Profile' page under the 'HTTP API' and update the iCalendar links afterwards.
Permanent link for public information only:
Permanent link for all public and protected information:
The discovery of X rays was made possible by the intelligent use of the best accelerator of the time. Since then, the development of particle accelerators has been at the root of both fundamental discoveries in physics and unforeseeable medical applications. The lecture will describe the major steps in this 120-year history of diagnostics and tumour therapy.
The first attempts to heal tumours with X rays were made only one month after Röntgen’s discovery, but the understanding of the mechanisms by which the radiation kills the cells and the introduction of dose fractionation took much longer. The use of X rays in diagnostics developed much faster and its benefits were very visible during the First World War. Today no tumour could be treated and no patient could be operated without a CT scan, which employs an X ray tube that is not very different from the one introduced by William Coolidge in 1912.
On the particle therapy frontier, more sophisticated and larger particle accelerators have contributed to the continuous increase of the tumour control rate. The initial betatrons were substituted, at the end of the 1950s, by radiofrequency electron linacs. More recently proton and carbon ion accelerators have become important tools in the fight against tumours, in particular “radio-resistant” tumours. After a review of the rationale for all forms of radiotherapy and of the accelerators used in proton therapy, the European centres for carbon ion therapy will be discussed and the challenges facing the physicists and the engineers developing the accelerators will be described.